BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29449224)

  • 21. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
    Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
    Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
    Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression Profiles of Ligands for Activating Natural Killer Cell Receptors on HIV Infected and Uninfected CD4⁺ T Cells.
    Tremblay-McLean A; Bruneau J; Lebouché B; Lisovsky I; Song R; Bernard NF
    Viruses; 2017 Oct; 9(10):. PubMed ID: 29023371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
    Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
    Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [An immunological approach to acute myeloid leukaemia].
    González B; Bueno D; Rubio PM; San Román S; Plaza D; Sastre A; García-Miguel P; Fernández L; Valentín J; Martínez I; Pérez-Martínez A
    An Pediatr (Barc); 2016 Apr; 84(4):195-202. PubMed ID: 26776165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.
    Braciak TA; Wildenhain S; Roskopf CC; Schubert IA; Fey GH; Jacob U; Hopfner KP; Oduncu FS
    J Transl Med; 2013 Nov; 11():289. PubMed ID: 24237598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.
    Khanuntong S; Kuptawintu P; Upaisilpsathaporn K; Poolchareon A; Bunworasate U; Hirankarn N
    HLA; 2016 Jun; 87(6):422-31. PubMed ID: 27273744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
    Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
    Front Immunol; 2021; 12():796072. PubMed ID: 34956230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML.
    Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
    J Investig Med; 2016 Dec; 64(8):1252-1260. PubMed ID: 27388616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
    Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
    Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
    Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
    Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.
    Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
    Eur J Haematol; 2016 Dec; 97(6):517-527. PubMed ID: 27096305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
    Front Immunol; 2021; 12():665541. PubMed ID: 33986753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
    Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
    J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells.
    Dulphy N; Chrétien AS; Khaznadar Z; Fauriat C; Nanbakhsh A; Caignard A; Chouaib S; Olive D; Toubert A
    Front Immunol; 2016; 7():94. PubMed ID: 27014273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.
    Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S
    Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
    Krupka C; Lichtenegger FS; Köhnke T; Bögeholz J; Bücklein V; Roiss M; Altmann T; Do TU; Dusek R; Wilson K; Bisht A; Terrett J; Aud D; Pombo-Villar E; Rohlff C; Hiddemann W; Subklewe M
    Oncotarget; 2017 May; 8(22):35707-35717. PubMed ID: 28415689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
    Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
    Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission.
    Ikegawa S; Doki N; Kurosawa S; Yamaguchi T; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Hattori K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Haraguchi K; Okuyama Y; Ohashi K
    Leuk Lymphoma; 2016; 57(6):1375-81. PubMed ID: 26422713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.